aTyr Pharma Announces Leadership Transition
October 15 2018 - 4:30PM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel immunological pathways, today announced the resignation of
David J. King, Ph.D. as Chief Scientific Officer of aTyr, effective
as of December 31, 2018. Dr. King will be pursuing an opportunity
as a founder of a private biotechnology company in a
non-competitive area and in biology distinct from aTyr. Through the
end of the year, Dr. King will assist in transition activities and
recruitment of new leadership to continue aTyr’s research efforts.
Dr. King will continue to serve as a scientific consultant for aTyr
into 2019.
“Our team has made tremendous progress in
elucidating this new area of biology and laying the groundwork for
potential therapeutic applications. I’m happy to have been a part
of the advancement of tRNA synthetase biology, particularly our
identification of the neuropilin-2 receptor for ATYR1923 and the
expanding knowledge of the role of that receptor,” said Dr. King.
“I’m leaving aTyr to pursue a life-long goal of founding a company.
I am privileged to have worked with the tremendously talented aTyr
team and remain very enthusiastic about the company’s science and
the potential benefit of ATYR1923 for patients.”
“On behalf of aTyr, I would like to thank David
for his efforts and scientific leadership over the past two years,
and we are pleased that he will remain with us as an advisor
following this transition,” said Sanjay Shukla, M.D., M.S.,
president and CEO of aTyr Pharma. “Over the coming months, David
and I will work closely together to implement this transition in an
effective manner.”
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
immunological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality of tRNA synthetases. aTyr has built a
global intellectual property estate directed to a potential
pipeline of protein compositions derived from 20 tRNA synthetase
genes. aTyr is focused on the therapeutic translation of the
Resokine pathway, comprised of extracellular proteins derived from
the histidyl tRNA synthetase gene family. ATYR1923 is a
clinical-stage product candidate which binds to the neuropilin-2
receptor and is designed to down-regulate immune engagement in
interstitial lung diseases and other immune-mediated diseases. For
more information, please visit http://www.atyrpharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Litigation Reform Act. Forward-looking
statements are usually identified by the use of words such as
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“may,” “plans,” “projects,” “seeks,” “should,” “will,” and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by such safe harbor
provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements, including statements
regarding the potential therapeutic benefits and applications of
our product candidates; our ability to successfully advance our
product candidates and accomplish certain development goals; and
the scope and strength of our intellectual property portfolio.
These forward-looking statements also reflect our current views
about our plans, intentions, expectations, strategies and
prospects, which are based on the information currently available
to us and on assumptions we have made. Although we believe that our
plans, intentions, expectations, strategies and prospects, as
reflected in or suggested by these forward-looking statements, are
reasonable, we can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those
described in these forward-looking statements and will be affected
by a variety of risks and factors that are beyond our control
including, without limitation, risks associated with the discovery,
development and regulation of our product candidates, the risk that
we may cease or delay preclinical or clinical development
activities for any of our existing or future product candidates for
a variety of reasons (including difficulties or delays in patient
enrollment in planned clinical trials), and the risk that we may
not be able to raise the additional funding required for our
business and product development plans, as well as those risks set
forth in our most recent Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q and in our other SEC filings. Except as
required by law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:Jason SparkManaging
Director, Canale Communications
Inc. jason@canalecomm.com619-849-6005
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024